• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biomarker Partnering Terms and Agreements Product Image

Biomarker Partnering Terms and Agreements

  • Published: April 2014
  • Region: Global
  • 987 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Biogen Idec
  • Eli Lilly
  • Hospira
  • Mylan
  • Sanofi
  • MORE

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of READ MORE >

TABLE OF CONTENTS

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Big pharma biomarker dealmaking activity
2.4. Most active biomarker dealmakers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7. Biomarker partnering by stage of development
2.8 Average deal terms for biomarkers
2.8.1 Biomarker headline values
2.8.2 Biomarker upfront payments
2.8.3 Biomarker milestone payments
2.8.4 Biomarker royalty rates
2.9. The anatomy of biomarker partnering
2.9. The anatomy of a biomarker deal
2.9.a. Case study 1: Kinemed, GlaxoSmithKline- June 2012
2.9.b. Case study 2: Roche, Rules-based Medicine, Psynova Neurotech- December 2009

Chapter 3 – Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving big pharma

Chapter 4 – Big pharma biomarker deals

4.1. Introduction
4.2. How to use big pharma biomarker partnering deals
4.3. Big pharma biomarker partnering company profiles
Abbott
Amgen
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva

Chapter 5 – Biomarker contracts dealmaking directory

5.1. Introduction
5.2. By Company A-Z
Abbott Laboratories
Adamis Pharmaceuticals
ADMA Biologics
Altair Nanotechnologies
Amarantus BioSciences
ARCA Biopharma
Arno Therapeutics
Arrayit 139
Arrayit Diagnostics
Avalon Pharmaceuticals
BG Medicine
Biogen Idec
Biotage
Caliper Life Sciences
Celera
Clinical Data
Columbia University
DeCODE Genetics
DiagnoCure
Enterome Bioscience
Galmed Pharmaceuticals
Gen-Probe
Genzyme
Genzyme Genetics
GlaxoSmithKline
Guided Therapeutics
Health Discovery
Intrexon
Inverness Medical Innovations
Invivis Pharmaceuticals
KineMed
Konica Minolta
Laboratory Corporation of America
Merck and Co
Novartis
Perugia University
Power3 Medical Products
Psynova Neurotech
Quest Diagnostics
Regulus Therapeutics
Response Genetics
Roche
Rules-Based Medicine
Sanofi
Skyline Diagnostics
The Regents of the University of California
Transgenomic
TrovaGene
University of Cambridge
University of Cincinnati
US Army
Wayne State University
Zora Biosciences
5.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Development
Distribution
Equity purchase
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Supply
5.4. By therapy area
Cardiovascular
Central Nervous System
Genetic disorders
Metabolic
Musculoskeletal
Oncology
Respiratory

Chapter 6 – Biomarker dealmaking by technology type

6.1. Introduction
6.2. Deals by biomarker type
Biomarkers

Chapter 7 – Biomarker partnering resource center

7.1. Online biomarker partnering
7.2. Biomarker partnering events
7.3. Further reading on biomarker dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports

Table of figures

Figure 1: Biomarker partnering since 2009
Figure 2: Big pharma – top 50 – biomarker deals 2009 to 2014
Figure 3: Big pharma biomarker deal frequency – 2009 to 2014
Figure 4: Active biomarker dealmaking activity– 2009 to 2014
Figure 5: Biomarker partnering by deal type since 2009
Figure 6: Biomarker partnering by disease type since 2009
Figure 7: Biomarker partnering by oncology target since 2009
Figure 8: Biomarker partnering by deal type since 2009
Figure 9: Biomarker deals with a headline value
Figure 10: Biomarker deal headline value distribution, US$million – 2009-2014– Discovery stage
Figure 11: Biomarker deal headline value distribution, US$million – 2009-2014 – preclinical stage
Figure 12: Biomarker deal headline value distribution, US$million – 2009-2014– phase I stage
Figure 13: Biomarker deal headline value distribution, US$million – 2009-2014– phase II stage
Figure 14: Biomarker deal headline value distribution, US$million – 2009-2014– phase III stage
Figure 15: Biomarker deal headline value distribution, US$million – 2009-2014– regulatory stage
Figure 16: Biomarker deal headline value distribution, US$million – 2009-2014– marketed stage
Figure 17: Summary median headline value by stage of development, 2009-2014
Figure 18: Biomarker deals with an upfront value
Figure 19: Biomarker deal upfront value distribution, US$million – 2009-2014– discovery stage
Figure 20: Biomarker deal upfront value distribution, US$million – 2009-2014– preclinical stage
Figure 21: Biomarker deal upfront value distribution, US$million – 2009-2014– phase I stage
Figure 22: Biomarker deal upfront value distribution, US$million – 2009-2014– phase II stage
Figure 23: Biomarker deal upfront value distribution, US$million – 2009-2014– phase III stage
Figure 24: Biomarker deal upfront value distribution, US$million – 2009-2014– regulatory stage
Figure 25: Biomarker deal upfront value distribution, US$million – 2009-2014– marketed stage
Figure 26: Summary median headline value by stage of development, 2009-2014
Figure 27: Biomarker deals with a milestone value
Figure 28: Biomarker deal milestone value distribution, US$million – 2009-2014– discovery stage
Figure 29: Biomarker deal milestone value distribution, US$million – 2009-2014– preclinical stage
Figure 30: Biomarker deal milestone value distribution, US$million – 2009-2014– phase I stage
Figure 31: Biomarker deal milestone value distribution, US$million – 2009-2014– phase II stage
Figure 32: Biomarker deal milestone value distribution, US$million – 2009-2014– phase III stage
Figure 33: Biomarker deal milestone value distribution, US$million – 2009-2014– regulatory stage
Figure 34: Biomarker deal milestone value distribution, US$million – 2009-2014– marketed stage
Figure 35: Biomarker deals with a royalty rate value
Figure 36: Biomarker deal royalty rate value distribution, US$million – 2009-2014– discovery stage
Figure 37: Biomarker deal royalty rate value distribution, US$million – 2009-2014– preclinical stage
Figure 38: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase I stage
Figure 39: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase II stage
Figure 40: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase III stage
Figure 41: Biomarker deal royalty rate value distribution, US$million – 2009-2014– regulatory stage
Figure 42: Biomarker deal royalty rate value distribution, US$million – 2009-2014– marketed stage
Figure 43: Summary median headline value by stage of development, 2009-2014
Figure 44: Components of the typical biomarker deal structure
Figure 44: Top biomarker deals by value since 2009
Figure 45: Top biomarker deals signed by big pharma value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo
Forest
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB view
Valeant
Warner Chilcott

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos